Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Astellas Pharma and BioFocus Sign Target Discovery Agreement
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
BioFocus has announced that it has signed a collaboration agreement with Astellas Pharma Inc. focused on discovering novel targets in the field of CNS disorders.
Under the agreement, BioFocus will utilize its SilenceSelect® target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration.
“We are delighted to support Astellas Pharma in its research” said Dr Chris Newton, SVP Galapagos Services and Managing Director BioFocus. “Our target discovery offering allows clients to access a unique platform providing rapid identification of novel targets through a proven technology”.
Under the agreement, BioFocus will utilize its SilenceSelect® target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration.
“We are delighted to support Astellas Pharma in its research” said Dr Chris Newton, SVP Galapagos Services and Managing Director BioFocus. “Our target discovery offering allows clients to access a unique platform providing rapid identification of novel targets through a proven technology”.
